Cardiovascular adverse events associated with targeted therapies for multiple myeloma: a pharmacovigilance study
MM-targeted therapy is significantly associated with an increased risk of previously unknown cardiovascular AE profiles, with the range and onset differing among various drugs, thereby warranting specific monitoring and appropriate management.
Authors
- Yunlong Xia (ORCID: https://orcid.org/0000-0003-4791-9666)
- Chang Shan
- Xinxin Zhang (ORCID: https://orcid.org/0000-0002-2918-9447)
- Yanli Zhang (ORCID: https://orcid.org/0000-0002-8942-5325)
- Yanfeng Wang (ORCID: https://orcid.org/0000-0002-3196-2347)
- Ying Liu (ORCID: https://orcid.org/0000-0001-5532-8554)
Institutions
- Dalian Medical University (CN)
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- First Affiliated Hospital of Dalian Medical University (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2024-09-26
- DOI
- https://doi.org/10.3389/fimmu.2024.1400101
- Citations
- 4
- Primary Topic
- Multiple Myeloma Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 1.82
Funders
- U.S. Food and Drug Administration